EA202190308A1 - Применение пролекарств рилузола для лечения болезни альцгеймера - Google Patents
Применение пролекарств рилузола для лечения болезни альцгеймераInfo
- Publication number
- EA202190308A1 EA202190308A1 EA202190308A EA202190308A EA202190308A1 EA 202190308 A1 EA202190308 A1 EA 202190308A1 EA 202190308 A EA202190308 A EA 202190308A EA 202190308 A EA202190308 A EA 202190308A EA 202190308 A1 EA202190308 A1 EA 202190308A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- riluzole
- disease
- alzheimer
- drugs
- treatment
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004181 riluzole Drugs 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YBZSGIWIPOUSHY-UHFFFAOYSA-N troriluzole Chemical compound NCC(=O)NCC(N(CC(NC=1SC2=C(N=1)C=CC(=C2)OC(F)(F)F)=O)C)=O YBZSGIWIPOUSHY-UHFFFAOYSA-N 0.000 abstract 1
- 229940121629 troriluzole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701814P | 2018-07-22 | 2018-07-22 | |
| PCT/US2019/042718 WO2020023324A1 (en) | 2018-07-22 | 2019-07-20 | Use of riluzole prodrugs to treat alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190308A1 true EA202190308A1 (ru) | 2021-05-19 |
Family
ID=69181140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190308A EA202190308A1 (ru) | 2018-07-22 | 2019-07-20 | Применение пролекарств рилузола для лечения болезни альцгеймера |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12161633B2 (https=) |
| EP (1) | EP3823616A4 (https=) |
| JP (2) | JP2021530543A (https=) |
| KR (1) | KR20210034621A (https=) |
| CN (1) | CN112469408A (https=) |
| AU (1) | AU2019310013B2 (https=) |
| BR (1) | BR112021000768A2 (https=) |
| CA (1) | CA3107215A1 (https=) |
| EA (1) | EA202190308A1 (https=) |
| IL (1) | IL280177B2 (https=) |
| MX (2) | MX2021000515A (https=) |
| NZ (1) | NZ772009A (https=) |
| PH (1) | PH12021550043A1 (https=) |
| SG (1) | SG11202100385YA (https=) |
| WO (1) | WO2020023324A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230027189A (ko) * | 2020-06-24 | 2023-02-27 | 바이오하벤 테라퓨틱스 리미티드 | 강박 장애를 치료하기 위한 조성물 및 방법 |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
| WO2022178425A1 (en) * | 2021-02-22 | 2022-08-25 | Yale University | Targeted bifunctional degraders |
| CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214663B2 (en) * | 2000-06-14 | 2007-05-08 | Medarex, Inc. | Tripeptide prodrug compounds |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| EP3079692A4 (en) | 2013-12-09 | 2017-10-18 | Thomas Jefferson University | Novel methods of treating a neurodegenerative disease in a mammal in need thereof |
| WO2016085998A1 (en) * | 2014-11-26 | 2016-06-02 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
| WO2017201502A1 (en) * | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| WO2018031707A1 (en) * | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| AU2019223014B2 (en) * | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| EP4277624B1 (en) * | 2021-01-18 | 2026-01-14 | Biohaven Therapeutics Ltd. | Troriluzole for use in the treatment of alzheimer's disease of mild severity |
-
2019
- 2019-07-20 WO PCT/US2019/042718 patent/WO2020023324A1/en not_active Ceased
- 2019-07-20 CA CA3107215A patent/CA3107215A1/en active Pending
- 2019-07-20 JP JP2021503571A patent/JP2021530543A/ja active Pending
- 2019-07-20 US US17/261,057 patent/US12161633B2/en active Active
- 2019-07-20 EA EA202190308A patent/EA202190308A1/ru unknown
- 2019-07-20 KR KR1020217004639A patent/KR20210034621A/ko not_active Ceased
- 2019-07-20 IL IL280177A patent/IL280177B2/en unknown
- 2019-07-20 EP EP19841953.3A patent/EP3823616A4/en active Pending
- 2019-07-20 NZ NZ772009A patent/NZ772009A/en unknown
- 2019-07-20 AU AU2019310013A patent/AU2019310013B2/en active Active
- 2019-07-20 BR BR112021000768-7A patent/BR112021000768A2/pt unknown
- 2019-07-20 CN CN201980048687.7A patent/CN112469408A/zh active Pending
- 2019-07-20 SG SG11202100385YA patent/SG11202100385YA/en unknown
- 2019-07-20 MX MX2021000515A patent/MX2021000515A/es unknown
-
2021
- 2021-01-07 PH PH12021550043A patent/PH12021550043A1/en unknown
- 2021-01-14 MX MX2024010655A patent/MX2024010655A/es unknown
-
2025
- 2025-02-21 JP JP2025026643A patent/JP2025093952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112469408A (zh) | 2021-03-09 |
| EP3823616A1 (en) | 2021-05-26 |
| US20210290599A1 (en) | 2021-09-23 |
| SG11202100385YA (en) | 2021-02-25 |
| BR112021000768A2 (pt) | 2021-05-11 |
| NZ772009A (en) | 2026-02-27 |
| WO2020023324A1 (en) | 2020-01-30 |
| IL280177A (en) | 2021-03-01 |
| EP3823616A4 (en) | 2022-05-04 |
| IL280177B1 (en) | 2024-09-01 |
| IL280177B2 (en) | 2025-01-01 |
| MX2021000515A (es) | 2021-06-08 |
| US12161633B2 (en) | 2024-12-10 |
| KR20210034621A (ko) | 2021-03-30 |
| CA3107215A1 (en) | 2020-01-30 |
| PH12021550043A1 (en) | 2021-09-20 |
| JP2021530543A (ja) | 2021-11-11 |
| AU2019310013A1 (en) | 2021-02-11 |
| AU2019310013B2 (en) | 2025-01-02 |
| JP2025093952A (ja) | 2025-06-24 |
| MX2024010655A (es) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
| BR112016025997A8 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JOP20190191A1 (ar) | وحدات شجرية علاجية | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| ZA202002626B (en) | Use of riluzole prodrugs to treat ataxias | |
| JOP20200242A1 (ar) | مركبات البلاديينوليد واستخداماتها | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| MX382357B (es) | Métodos y composiciones para tratar infecciones fúngicas cutáneas. | |
| PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| JOP20190278A1 (ar) | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| EA202190406A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| EA202091162A1 (ru) | Применение пролекарств рилузола для лечения атаксии | |
| MX2024007070A (es) | Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. |